

Regd. Office: 93, J. P. Road, Andheri (West), Mumbai - 400 058. • Phone: 67 603 603 • Fax: 91-22-6694 3127 Email : info@jenburkt.com • www.jenburkt.com • CIN No. L24230MH1985PLCO36541

Part I		the IIndQuarter and Half Year ended on 30/09/2015 (`in Lacs							
Sr. No.	Particulars		Quarter ended		Half Year Ended		Year ended		
		30/09/2015	30/06/2015	30/09/2014	30/09/2015	30/09/2014	31/03/2015		
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited		
1	Income from Operations								
	a) Net Sales/Income from Operations (Net of								
	Excise Duty)	2512.57	2184.31	2222.40	4696.88	4143.33	8501.8		
	b) Other Operating Income	5.25	37.74	1.95	42.99	3.67	19.2		
	Total Income from Operations (Net)	2517.82	2222.05	2224.35	4739.87	4147.00	8521.0		
2	Expenses								
	a) Cost of Materials Consumed	180.92	173.95	763.17	354.87	1308.73	2657.0		
	b) Purchases of Stock in Trade	712.71	484.46	0.47	1197.17	1.15	1.4		
	c) Changes in Inventories of Finished Goods,								
	Work-in-progress and Stock-in-Trade	-116.62	8.29	-71.80	-108.33	-43.69	-65.2		
	d) Employee benefits Expense	509.33	548.99	454.13	1058.32	943.08	1899.3		
	e) Depriciation and amortisation Expense	46.73	45.75	48.50	92.48	86.00	265.9		
	f) Other Expenses	706.46	645.37	626.15	1351.83	1234.15	2503.2		
	Total Expenses	2039.53	1906.81	1820.62	3946.34	3529.42	7261.6		
	Profit / (Loss) from Operations before other				00 10.0 1	0020112	720210		
3	income, finance cost and exceptional items (1-	470.20	245.24	402.72	702 50	547.50			
4	Other Income	478.29	315.24	403.73	793.53	617.58	1259.4		
-4	Profit / (Loss) from Ordinary activities before	59.54	58.90	24.43	118.44	30.77	207.2		
5									
	finance costs and exceptional items (3+4)	537.83	374.14	428.16	911.97	648.35	1466.6		
6	Finance Cost	7.34	10.39	4.66	17.73	16.19	35.6		
7	Profit / (Loss) from ordinary activities after								
	finance cost but before exceptional items (5-6)	530.49	363.75	423.50	894.24	632.16	1431.0		
8	Exceptional Items	0.10	0.00	0.00	0.10	0.16	2.9		
9	Profit / (Losss) from Ordinary activities before								
	tax (7+8)	530.59	363.75	423.50	894.34	632.32	1433.9		
10	Tax Expense								
	Direct Tax	201.18	100.15	120.00	301.33	180.00	512.5		
	Deffered Tax	-13.52	8.25	-21.25	-5.27	-21.25	-43.4		
11	Net Profit / (Loss) from Ordinary activities after								
11	tax (9-10)	342.93	255.35	324.75	598.28	473.57	964.9		
12	Extra ordinary items	0.00	0.00	0.00	0.00	0.00	0.0		
13	Net Profit / (Loss) for the period (11+12)	342.93	255.35	324.75	598.28	473.57	964.9		
14	Share of Profit / (Loss of Associates)	0.00	0.00	0.00	0.00	0.00	0.0		
15	Minority Interest	0.00	0.00	0.00	0.00	0.00	0.0		
	Net Profit / (Loss) after taxes, minority interest						0.0		
16	and share of profit/(loss) of Associates								
	(13+14+15)	342.93	255.35	324.75	598.28	473.57	964.9		
17	Paid-up equity share capital (Face Value of Rs.								
	10/- each)	464.93	464.93	464.93	464.93	464.93	464.9		
18	Reserve excluding Revaluation Reserves (as per						.51.5		
	balance sheet of previous accounting year)						2878.9		
	Earnings Per Share (EPS) (before and after								
	extraordinary items) (of Face Value of Rs. 10/-					ı			
	each) (not annualised)						8 7		
	Basic and Diluted	7.38	5.49	6.98	12.87	10.19	20.75		





Regd. Office: 93, J. P. Road, Andheri (West), Mumbai - 400 058. • Phone: 67 603 603 • Fax: 91-22-6694 3127 Email : info@jenburkt.com • www.jenburkt.com • CIN No. L24230MH1985PLCO36541

	P	art - I			
	UNAUDITED STATEMENT OF ASSETS	AND LIAI	BILITIES AS A	Г 30/09/201	15
					(Rs. in Lacs
	Particulars		30/09/2015		31/03/2015
Α.	EQUITY & LIABILITIES				
1	Share Holders Fund				
	a) Share Capital	464.93		464.93	
	b) Reserves & Surplus	3477.21		2878.94	
	c) Money received against Share warrants	0.00		0.00	
	Sub-total Shareholders' fund		3942.14		3343.8
2	Share application money pending allotment		0.00		0.0
3	Minority Interest		0.00		0.0
4	Non Current Liabilities				
	a) Long Term Borrowings	0.00		0.63	
	b) Defferred Tax Liability (Net)	70.99		76.26	
	c) Other Long Term Liabilities	278.29		269.29	
	d) Long Term Provisions	0.00		0.00	
	Sub total Non-current liabilities		349.28		346.1
5	Current Liabilities				
	a) Short Term Borrowings	242.94		660.8	
	b) Trade Payables	640.66		382.33	
	c) Other Current Liabilities	573.05		479.89	
	d) Short Term Provisions	4.67		872.20	
	Sub total Current liabilities		1461.32		2395.2
	TOTAL - EQUITY AND LIABILITIES		5752.74		6085.2
В.	ASSETS				
1	Non Current Assets				
	a) Fixed Assets	1207.23		1160.45	
	b) Non Current Investments	31.21		31.21	
	c) Defferred Tax Assets (Net)	0.00		0.00	1
	d) Long Term Loans & Advances	0.00		0.00	
	e) Other Non Current assets	33.26		33.26	
	Sub total Non-current assets		1271.70		1224.9
2	Current Assets				
	a) Current Investments	15.00		0.00	
	b) Inventories	832.32		758.04	
	c) Trade Receivables	559.42		737.52	
	d) Cash & Cash Equivalents	2956.05		2750.78	2-7-11-27-20-2-10
	e) Short Term Loans & Advances	65.27		48.99	
,	f) Other Current Assets	52.98		565.02	
	Sub total - Current assets	32,30	4481.04	303.02	4860.3
	TOTAL ASSETS		5752.74		6085.2





Jenburkt Pharmaceuticals Ltd.

Regd. Office: 93, J. P. Road, Andheri (West), Mumbai - 400 058. • Phone: 67 603 603 • Fax: 91-22-6694 3127 Email : info@jenburkt.com • www.jenburkt.com • CIN No. L24230MH1985PLCO36541

PART II									
Α	В	С	D		E	F		G	1
Sr. No	Particulars		Quarter ended			Half Year Ended			Year ended
		30/09/15	30/06/15	30/09/14		30/09/15	30/09/14		31/03/15
		Unaudited	Unaudited	Unaudited		Unaudited	Unaudited		Audited
1	Public shareholding - Number of shares - Percentage of shareholding	2521130 54.23	2513833 54.07	2466223 53.05		2521130 54.23	2466223 53.05		2494513 53.65
2	Promoters and Promoter Group Shareholding a) Pledged / Encumbered - Number of shares	0	0	0		0	0		0
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0	0	0		0	0		0
	- Percentage of shares (as a % of the total share capital of the company) b) Non - encumbered	0	0	0		0	0		0
	- Number of shares - Percentage of shares (as a %	2128170	2135467	2183077		2128170	2183077		2154787
	of the total shareholding of the Promoter and Promoter group)	100.00	100.00	100.0	00	100.00	100.0	00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	45.77	45.93	93 46.95		45.77	46.95	46.35	
	Particulars	30/09/2015							
В	INVESTOR COMPLAINTS Pending at the beginning of the quarter	Nil							
	Received during the quarter Disposed of during the	2							
	quarter Remaining unresolved at the end of the quarter	Nil			i ja				

Notes:

- 1. The above unaudited results were reviewed by the Audit Committee and taken on record by the Board of the Directors of the Company at their Respective meetings held on 27th October, 2015.
- 2. The Limited Review of the quaterly results has been carried out by the Statutory Auditors.
- 3. The Company is dealing exclusively in pharmaceuticals business segment, hence segmentwise presentation of financial result is not applicable.
- 4. Figures of previous quarter/year are regrouped/ rearranged, wherever necessary.

Place :Mumbai

Date: 27th October, 2015

By order of the Board

For Jenburkt Pharmaceuticals Ltd.

Ashish U Bhuta

Chairman and Managing Director



D.L.ARORA & Co. CHARTERED ACCOUNTANTS

Independent Auditor's Review Report

TO
THE BOARD OF DIRECTORS,
JENBURKT PHARMACEUTICALS LIMITED,
Mumbai

We have reviewed the accompanying statement of unaudited statement of financial result of **Jenburkt Pharmaceuticals Limited** ("the company") for the quarter ended 30th September, 2015, attached herewith, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from the records furnished to us by the management and have not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Engagements to review financial information issued by the Institute of Chartered Accountant of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquires of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D.L.Arora & Co. Chartered Accountants

MEMBERSHIP NUMBER:

36152

FRN.: 100545W

Dilip Arora Proprietor

M. No.: 036152

Place: Mumbai. Date: 27/10/2015

E:\My Documents - 1\Jenburkt\JPL 15-16\Limited review report.